Center Book Partners LP Halozyme Therapeutics, Inc. Transaction History

Center Book Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $670,048 - $1.14 Million	20,391 Added 153.13%	33,707 $1.29 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $264,996 - $393,195	-6,615 Reduced 33.19%	13,316 $757,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $379,250 - $509,670	9,843 Added 97.57%	19,931 $788,000
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $374,471 - $484,255	-10,026 Reduced 49.85%	10,088 $444,000
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $232,997 - $299,245	7,288 Added 56.82%	20,114 $802,000
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $408,123 - $522,659	12,826 New	12,826 $516,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

Stay updated on Center Book Partners LP with notifications on news.